Aurobindo Pharma on Thursday announced that its subsidiary, Auro Pharma, will acquire the non-oncology prescription formulations business of Khandelwal Laboratories on a going concern basis through a slump sale.
The acquisition will be carried out for a cash consideration of ₹325 crore, subject to customary true-up adjustments for working capital, as outlined in the definitive agreements, the company said in a regulatory filing, according to media reports.
The business being acquired comprises 23 brands marketed across 67 stock-keeping units (SKUs), along with nine pipeline products. Anti-infective and pain management therapies form the core portfolios of the business.
In FY25, the non-oncology prescription formulations business recorded a turnover of ₹113.5 crore and an EBITDA of ₹28.9 crore. It is supported by a field force of around 470 personnel and an extensive distribution network of over 1,600 stockists.
Effective January 1, 2026, the acquisition is expected to strengthen Aurobindo Pharma’s domestic formulations business by adding new brands in pain management and anti-infectives, complementing its existing product portfolio and expanding its presence in the Indian market.
Also Read